Value
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.0 |
| P/S | 9.4 |
| EV/EBITDA | 5.5 |
| Fwd P/E | 9.0 |
| PEG | 4.7 |
| Analyst target | 7.5 |
- ▸Forward P/E: 11.7x
- ▸PEG: 1.78
- ▸Attractively valued
GEHC · Why this verdict
Why GE HealthCare Technologies (GEHC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
GE HealthCare has a credible earnings delivery track record — three beats in the prior three quarters before the most recent miss — and a favorable risk/reward of roughly 2.1-to-1 with approximately 11% room to the analyst-derived target, but the stock is in a confirmed technical downtrend with a death cross in place and growth is soft, making the setup one that rewards patience until the chart stabilizes.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Three of the last four quarterly earnings reports produced positive surprises — beats of 15.4%, 2.2%, and 3.0% in the three quarters ending before the most recent period — demonstrating a pattern of consistent delivery against estimates even in a period of soft overall growth. Earnings | The next quarterly report (expected in approximately 43 days) returns to a positive earnings surprise, restoring the beat pattern after the most recent -5.7% miss. | →Stable |
| CounterThe most recent quarter produced a miss of -5.7% against estimates, ending the streak — and with growth near stagnant on the earnings line, the prior beats may have reflected a low-estimate starting point rather than accelerating business momentum. | ||
The stock is in a confirmed downtrend — below its 200-day moving average with that average declining at roughly 2.1% over 30 days, a death cross in force, and falling on-balance volume — indicating sellers remain in control and that buying pressure has not yet emerged at current price levels. Momentum breakdown | Price reclaims the 200-day moving average and on-balance volume turns positive within 6 months, confirming a reversal from the current downtrend. | ↓Deteriorating |
| CounterMACD is improving despite the death cross — a divergence between price-trend and momentum that the analysis characterizes as a recovery setup — suggesting underlying buying pressure may be building before the chart technically confirms. | ||
With approximately 11% upside to the analyst-derived price target and a risk/reward ratio of roughly 2.1-to-1 in favor of the long side, the current price offers a reasonable reward for the risk being taken — an asymmetry that holds even accounting for the cautious technical backdrop. Price targets | Price reaches within 3% of the target of $71.75 within 12 months, capturing the majority of the identified upside. | ↑Improving |
| CounterA 2.1-to-1 risk/reward is favorable but relatively modest; if the technical downtrend extends or growth disappoints further, the downside cushion may be consumed before the thesis has a chance to play out. | ||
Revenue growth is in low single digits and the earnings growth rate is effectively flat, creating a profile where the current valuation — while reasonable at a forward multiple of 12.1 times with a price-to-growth ratio of 1.83 — carries limited re-rating potential absent an acceleration in the fundamental growth trajectory. Bear case | Revenue growth accelerates above 6% year over year for 2 consecutive quarters, providing the earnings growth catalyst needed to support a meaningful multiple expansion. | ↓Deteriorating |
| CounterHealthcare equipment and imaging businesses often grow at modest revenue rates while generating reliable recurring revenues from installed bases — soft top-line growth may reflect a mature, steady franchise rather than deteriorating competitive position. | ||
The put/call ratio stands at 0.62, leaning decidedly toward call options relative to puts — a positioning skew that indicates options participants are more interested in upside exposure than downside protection at current levels, a signal that can precede a price recovery. Options | The put/call ratio stays below 0.80 for the next 3 months while price stabilizes, confirming that options-market participants maintain a bullish posture. | ↑Improving |
| CounterA low put/call ratio can reflect speculative call-buying rather than fundamental conviction — if the stock continues to decline, unhedged call buyers may reverse their positions, removing one source of potential buying support. | ||
Three of the last four quarterly earnings reports produced positive surprises — beats of 15.4%, 2.2%, and 3.0% in the three quarters ending before the most recent period — demonstrating a pattern of consistent delivery against estimates even in a period of soft overall growth.
→StableEarnings
- Expectation
- The next quarterly report (expected in approximately 43 days) returns to a positive earnings surprise, restoring the beat pattern after the most recent -5.7% miss.
CounterThe most recent quarter produced a miss of -5.7% against estimates, ending the streak — and with growth near stagnant on the earnings line, the prior beats may have reflected a low-estimate starting point rather than accelerating business momentum.
The stock is in a confirmed downtrend — below its 200-day moving average with that average declining at roughly 2.1% over 30 days, a death cross in force, and falling on-balance volume — indicating sellers remain in control and that buying pressure has not yet emerged at current price levels.
↓DeterioratingMomentum breakdown
- Expectation
- Price reclaims the 200-day moving average and on-balance volume turns positive within 6 months, confirming a reversal from the current downtrend.
CounterMACD is improving despite the death cross — a divergence between price-trend and momentum that the analysis characterizes as a recovery setup — suggesting underlying buying pressure may be building before the chart technically confirms.
With approximately 11% upside to the analyst-derived price target and a risk/reward ratio of roughly 2.1-to-1 in favor of the long side, the current price offers a reasonable reward for the risk being taken — an asymmetry that holds even accounting for the cautious technical backdrop.
↑ImprovingPrice targets
- Expectation
- Price reaches within 3% of the target of $71.75 within 12 months, capturing the majority of the identified upside.
CounterA 2.1-to-1 risk/reward is favorable but relatively modest; if the technical downtrend extends or growth disappoints further, the downside cushion may be consumed before the thesis has a chance to play out.
Revenue growth is in low single digits and the earnings growth rate is effectively flat, creating a profile where the current valuation — while reasonable at a forward multiple of 12.1 times with a price-to-growth ratio of 1.83 — carries limited re-rating potential absent an acceleration in the fundamental growth trajectory.
↓DeterioratingBear case
- Expectation
- Revenue growth accelerates above 6% year over year for 2 consecutive quarters, providing the earnings growth catalyst needed to support a meaningful multiple expansion.
CounterHealthcare equipment and imaging businesses often grow at modest revenue rates while generating reliable recurring revenues from installed bases — soft top-line growth may reflect a mature, steady franchise rather than deteriorating competitive position.
The put/call ratio stands at 0.62, leaning decidedly toward call options relative to puts — a positioning skew that indicates options participants are more interested in upside exposure than downside protection at current levels, a signal that can precede a price recovery.
↑ImprovingOptions
- Expectation
- The put/call ratio stays below 0.80 for the next 3 months while price stabilizes, confirming that options-market participants maintain a bullish posture.
CounterA low put/call ratio can reflect speculative call-buying rather than fundamental conviction — if the stock continues to decline, unhedged call buyers may reverse their positions, removing one source of potential buying support.
Per-dimension breakdown
Quality
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 6.5 |
| ROA | 3.4 |
| Gross margin | 3.8 |
| Op margin | 4.4 |
| Net margin | 4.6 |
| Current ratio | 4.7 |
| FCF quality | 5.8 |
| Moat | 5.5 |
| Piotroski F | 6.7 |
- ▸Earnings quality warning: 78% FCF/NI
Growth
2.1/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.3 |
| EPS growth | 0.0 |
Momentum
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 1.0 |
| Volume | 0.7 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -2.1%/30d — confirmed downtrend
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.4 |
| Price target | 8.4 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 28%
Insider
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 6.5 |
| insider conviction | 8.0 |
| holder change | 9.2 |
| notable moves | 5.0 |
- ▸Modest insider buying — $6,423,136 (0.022% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.6 |
| quality rank | 8.0 |
| growth rank | 4.0 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 9.8 |
| support resistance | 7.4 |
| 52w position | 3.8 |
| gap | 6.0 |
Risk (lower is worse)
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.2 |
| days to cover | 7.9 |
| volatility | 4.3 |
| put call | 0.0 |
| implied vol | 4.6 |
| max pain risk | 7.0 |
| beta | 8.0 |
| debt equity | 5.2 |
- ▸Elevated put/call: 2.23
Catalyst
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 4.4 |
| dividend safety | 7.5 |
- ▸Strong earnings: 3B/1M
- ▸Earnings in 8 days
- ▸Dividend aristocrat: 0.2% yield
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- ASYMMETRY:2.3>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:1.4<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (2)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:8d<=14d (soft)
Reward-to-Risk
2.31
Upside
+15.1%
Downside
6.5%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 8d with 3/4 beat streak
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Value at 7.3) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:1.4<4.5, DEATH_CROSS:HARD_BLOCK) reinforce the read. Current asymmetry R:R is 2.31 — supplementary context, not the trigger for this path.
The strongest dimensions are Value at 7.3, Insider at 7.2, and Sentiment at 7.1; the weakest are Momentum at 1.4, Growth at 2.1, and Quality at 5.0. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 2.31 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Delivery Record
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Confirmed Technical Downtrend
Trip ifPrice rises above the 200-day moving average and on-balance volume rises above its prior 20-day average for 20 or more consecutive trading days.
- P3Favorable Risk Reward Setup
Trip ifPrice falls more than 10% below the current level, compressing the upside-to-target ratio below 5%.
- P4Soft Growth Profile
Trip ifRevenue growth accelerates above 6% year over year for 2 consecutive quarters.
- P5Options Sentiment Bullish Lean
Trip ifPut/call ratio rises above 1.20 for 2 consecutive months, indicating a shift to net bearish positioning.